ArticleMilitary Medical Research2025
The national and provincial prevalence and non-fatal burdens of diabetes in China from 2005 to 2023 with projections of prevalence to 2050.
Article in Military Medical Research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07531459 (Compilation and Preliminary Application of the Active Health Behavior Scale in Patients With Type 2 Diabetes), which is not on this map. Cited by 68 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Compilation and Preliminary Application of the Active Health Behavior Scale in Patients With Type 2 Diabetes
Who cites it
68 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- National, regional and provincial prevalence of peripheral artery disease in Chinese adults in 2023: an updated systematic review and modelling study.Journal of global health · 2026Pooled it
- Knowledge, attitudes, and practices regarding diabetic foot care among patients with diabetes in China: a systematic review and meta-analysis.Frontiers in public health · 2026Pooled it
- The longitudinal association between artificial sweetener intake and the risk of type 2 diabetes among adults aged 18 years and older: a systematic review and meta-analysis.Frontiers in nutrition · 2026Pooled it
- Diabetes mellitus and risk of multiple sclerosis: a systematic review and meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Effectiveness of behavioural economics-based financial incentives and social feedback on glycaemic control and physical activity in adults with newly diagnosed type 2 diabetes: A randomised control trial.Diabetes, obesity & metabolism · 2026Trial
- Polyethylene Glycol Loxenatide Selectively Reduces Adiposity While Preserving Lean Body Mass in Type 2 Diabetes: A 12-Week Clinical Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Trial
- Epidemiological status and developmental trends of sexual violence among children and adolescents aged 0-19 years: a global analysis and projections.Annals of medicine · 2026Article
- Two-Time-Point Inflammatory Status Patterns and the Risk of Incident Diabetes: A Cohort Study Based on CHARLS.Healthcare (Basel, Switzerland) · 2026Article
- Global, Regional, and National Burden of Caries Among Women of Childbearing Age From 1990 to 2021 and Prediction.International dental journal · 2026Article
- East Asia and high-income Asia Pacific burden of diabetes mellitus from 1990 to 2023.iScience · 2026Article
- Multi-omics reveals goat milk improves glucose homeostasis in type 2 diabetes mellitus mice by gut-liver axis.Food chemistry: X · 2026Article
- The association between time in range with sarcopenia and its components in older patients with type 2 diabetes mellitus.Scientific reports · 2026Article
- Confined coordination regulation of rhodium in organosilica active framework for enhanced photothermal-enzymatic diabetic wound healing.Materials today. Bio · 2026Article
- Observational
- Oral Chitosan-Tripolyphosphate Nanoparticles Enhance the Metabolic Regulatory Effects of Snow Lotus Polysaccharide in Type 2 Diabetes.Pharmaceutics · 2026Article
- A Hospital-Wide informatized glycemic management Team(WH-GMT) improves perioperative outcomes in type 2 diabetes: A prospective cohort study.Endocrine · 2026Article
- Improved Glycaemic Control with IDegLira in Chinese Adults with Type 2 Diabetes in Real-World Settings: A Retrospective, Database Cohort Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Article
- Maternal PMParticle and fibre toxicology · 2026Article
- Multidimensional drivers of diabetes prevalence among middle-aged and elderly in China: from a geographical perspective.Diabetology & metabolic syndrome · 2026Article
- Bridging the perception-practice gap: a mixed-methods study on interprofessional collaboration for diabetes and periodontitis management.BMC oral health · 2026Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChina accounts for one-quarter of the world's diabetes population, with significant subnational disparities. However, none of the available data have provided comprehensive estimates and projections at both regional and national levels in diabetes prevention and management. This study aimed to explore the temporal trends and geographical variations in the prevalence and non-fatal burden of diabetes by age and sex across China from 2005 to 2023, and to forecast diabetes prevalence through 2050.
methodsWe conducted a population-based study based on the nationally representative surveys, and literature reviews. Using the DisMod-MR model and Chinese-specific disease disability weights, we estimated the non-fatal burdens of diabetes, including prevalence and years lived with disability (YLDs), across sexes, age groups, and locations. The temporal trend change was measured as the average annual percent change. The effect of the Human Development Index on burdens was assessed by applying Spearman's rank correlation analysis. We further projected diabetes prevalence to 2050 under two scenarios, the natural trend and the effective intervention on body mass index (BMI).
resultsIn 2023, an estimated 233 million individuals in China were living with diabetes. Compared to 2005, the age-standardized rate (ASR) of prevalence has increased by nearly 50%, from 7.53% (95% CI 7.00-8.10%) to 13.7% (95% CI 12.6-14.8%) in 2023. The ASR of YLDs was estimated at 19.1 per 1000 population (95% CI 18.6-19.5) in 2023, compared to 10.5 per 1000 population in 2005. The ASR of prevalence and YLDs was consistently higher in males than in females. The provinces with the highest diabetes prevalence and disease burden were Beijing, Tianjin, and Shanghai. Our forecast results suggest that if existing trends continue, the prevalence of obesity will reach 29.1% (95% CI 22.2-38.2%) nationally by 2050, with some provinces in the northern region observing a prevalence of over 40%. Conversely, if effective obesity interventions were implemented, the growth in diabetes prevalence could potentially be suppressed by nearly 50%.
conclusionsThe health burden and economic cost associated with diabetes are profound. There is an urgent need to scale up preventive efforts and improve population awareness to enhance disease management and achieve optimal treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.